Summary:
Chronic Kidney disease is emerging as a new health problem.
Therapy with angiotensin converting enzyme inhibitors (ACEI)
and angiotensin II receptor blockers (ARBs) have shown
improvement in patients with hypertension, proteinuria and
chronic renal failure. This improvement in GFR, fall in plasma
renin activity (PRA) is due to improved sympathetic activity,
improved endothelial function, reduced inflammation or
combination of these factors. Several large scale, prospective
randomized studies with clinical end point have strongly
suggested that both ACEI or ARBs can slow progression of
chronic glomerulonephritis alone. However, beneficial effect are
much pronounced in combined group. Both ACEI & ARBs can